Selegiline is indicated to treat Parkinson’s disease in combination with levodopa/carbidopa. Selegiline is a levorotatory acetylenic derivative of phenethylamine and a selective type B monoamine oxidase (MAO) inhibitor. It acts as a suicide substrate wherein MAO transforms it into an active moiety which irreversibly binds with the active site and/or the important flavin-adenine dinucleotide (FAD) cofactor of the enzyme, thereby blocking MAO activity. It may also elevate dopaminergic activity by inhibiting the re-uptake of dopamine at the synapse.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value and the acceptable surface limit (ASL).
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL monograph for this compound, just click the ADD TO CART button.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.